Image

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Study: Sacituzumab Tirumotecan and Pembrolizumab vs. Pembrolizumab in advanced lung cancer.

Recruiting
18 years and older
All
Phase 3

This study is for people with a type of lung cancer called non-small cell lung cancer (NSCLC). The researchers want to find out if a new drug combination works better than the current treatment. They are looking at a drug called sacituzumab tirumotecan combined with another drug called pembrolizumab, comparing it to using pembrolizumab alone. The main goal is to see which treatment helps people live longer.

Not everyone can join this study. You need to have a confirmed diagnosis of NSCLC with a certain protein called PD-L1 present in at least 50% of your tumor cells. You should not have had certain treatments before, and there are other health conditions that might prevent you from joining.

  • Study Length: You may receive treatment in up to 9 cycles if your disease progresses after the first course.
  • Visits Needed: Regular visits are required for treatment and check-ups.
  • Risks: Possible drug reactions and side effects; discuss with your doctor.

If you meet all the requirements and are interested, talk to your doctor about joining this study.

Study details
    Non-small Cell Lung Cancer (NSCLC)

NCT06170788

Merck Sharp & Dohme LLC

8 March 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.